ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

MNPR Monopar Therapeutics Inc

0.734
0.074 (11.21%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Monopar Therapeutics Inc MNPR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.074 11.21% 0.734 18:11:34
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.67 0.6433 0.7624 0.7272 0.66
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/4/202407:00GLOBEMonopar Announces Radiopharma Presentation Selected for..
16/4/202407:00GLOBEMonopar Announces Filing of Patent Protecting MNPR-101..
10/4/202407:00GLOBEMonopar Initiates Radiopharma Phase 1 Clinical Trial for..
28/3/202406:00GLOBEMonopar Reports Fourth Quarter and Full-Year 2023 Financial..
07/3/202407:30EDGAR2Form 8-K - Current report
05/3/202406:00EDGAR2Form 8-K - Current report
05/3/202406:00GLOBEMonopar Announces Positive Preclinical Therapeutic Isotope..
28/2/202412:45EDGAR2Form 8-K - Current report
27/2/202406:00GLOBEMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical..
27/2/202405:59EDGAR2Form 8-K - Current report
22/2/202406:00EDGAR2Form 8-K - Current report
22/2/202406:00GLOBEMonopar Announces Promising Preclinical Data for its..
20/2/202407:00EDGAR2Form 8-K - Current report
20/2/202407:00GLOBEMonopar Receives Clearance to Proceed with First-in-Human..
03/1/202418:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202418:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202306:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:00EDGAR2Form 8-K - Current report
09/11/202306:00GLOBEMonopar Therapeutics Reports Third Quarter 2023 Financial..
01/11/202306:00EDGAR2Form 8-K - Current report
01/11/202306:00GLOBEMonopar Presents Data Showing Tumor Reduction Benefit of..
10/10/202306:00GLOBEMonopar to Participate in the Roth MKM 2023 Healthcare..
03/10/202318:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202318:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202306:00GLOBEMonopar to Participate in the H.C. Wainwright 25th Annual..
30/8/202316:16EDGAR2Form 8-K - Current report
10/8/202306:00EDGAR2Form 8-K - Current report
10/8/202306:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202306:00GLOBEMonopar Therapeutics Reports Second Quarter 2023 Financial..
08/8/202306:00EDGAR2Form 8-K - Current report
08/8/202306:00GLOBEMonopar Provides Encouraging Camsirubicin Clinical Data..
11/7/202306:00EDGAR2Form 8-K - Current report
11/7/202306:00GLOBEMonopar Announces MNPR-101 Radiopharma Collaboration..
03/7/202317:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202317:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202315:13EDGAR2Form 8-K - Current report
21/6/202306:00GLOBEMonopar to Participate in the Radiopharma Forum by the Lake..
14/6/202306:00GLOBEMonopar to Participate in the Maxim Group’s Healthcare..
01/6/202306:00GLOBEMonopar Announces Encouraging Camsirubicin Phase 1b Trial..
11/5/202306:00GLOBEMonopar Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock